PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 81.7% in June

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 57,440 shares, a drop of 81.7% from the May 31st total of 313,070 shares. Based on an average daily volume of 4,968,100 shares, the short-interest ratio is presently 0.0 days. Approximately 10.1% of the shares of the stock are short sold.

PainReform Stock Down 5.6%

Shares of PRFX stock traded down $0.09 during trading on Friday, hitting $1.51. The company had a trading volume of 432,114 shares, compared to its average volume of 6,596,596. The stock’s 50-day moving average is $1.83 and its two-hundred day moving average is $2.83. The stock has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.00 and a beta of 0.98. PainReform has a 52 week low of $1.28 and a 52 week high of $17.95.

PainReform (NASDAQ:PRFX) last announced its earnings results on Thursday, March 26th. The company reported ($1.01) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PainReform in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.